Evaluating the in-silico toxicity profile of the other available marketed drugs against the BRAF overexpression cancer such as sorafeniib, TAK-632 our selected antagonist would have the more possibility to reduce the side effects currently possible anti-cancer treatments. The gene discussed is BRAF; the disease is cancer.